Walldorf, Baden-Wurttemberg, Germany The leading representative office of defined Corporate Investor is situated in the Walldorf. The fund was located in Europe if to be more exact in Germany.
The standard case for the fund is to invest in rounds with 2 partakers. Despite the dievini Hopp Biotech Holding, startups are often financed by Wellington Partners, OH Beteiligungen, DH Capital. The meaningful sponsors for the fund in investment in the same round are Wellington Partners, AT Impf, Sigma Group. In the next rounds fund is usually obtained by Wellington Partners, AT Impf, Bill & Melinda Gates Foundation.
Among the most popular portfolio startups of the fund, we may highlight CureVac, Apogenix, Novaliq. For fund there is a match between the country of its foundation and the country of its the most frequent investments - Germany. The fund has exact preference in some founders of portfolio startups. Among the most popular fund investment industries, there are Therapeutics, Biopharma. Moreover, a startup needs to be at the age of 6-10 years to get the investment from the fund.
The common things for fund are deals in the range of 10 - 50 millions dollars. The fund is generally included in less than 2 deals every year. This dievini Hopp Biotech Holding works on 22 percentage points less the average amount of lead investments comparing to the other organizations. The higher amount of exits for fund were in 2016. The typical startup value when the investment from dievini Hopp Biotech Holding is more than 1 billion dollars. The high activity for fund was in 2012. Speaking about the real fund results, this Corporate Investor is 40 percentage points more often commits exit comparing to other organizations.
This organization was formed by Christof Hettich, Friedrich Bohlen. The overall number of key employees were 2.
Related Funds
Funds with similar focus
Notable deals
| Company | Industry | Round Size | Date | Investors | Location |
Apogenix | $8M | 28 Feb 2012 | Heidelberg, Baden-Württemberg, Germany | ||
Novaliq | $2M | 27 Jul 2011 | Heidelberg, Baden-Württemberg, Germany | ||
immatics biotechnologies | $63M | 21 Sep 2010 | Germany, Baden-Württemberg, Germany | ||
CureVac | $34M | 10 May 2010 | Germany, Baden-Württemberg | ||
Apogenix | $32M | 30 Apr 2008 | Heidelberg, Baden-Württemberg, Germany |
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Full teamIndustries heatmapStages heatmapGeorgaphy breakdownCoinvestorsPortfolio analysisPerformance indexesLatest highlights
Unlock all data Latest deals
| Company | Industry | Round Size | Date | Investors | Location |
Apogenix | $8M | 28 Feb 2012 | Heidelberg, Baden-Württemberg, Germany | ||
Novaliq | $2M | 27 Jul 2011 | Heidelberg, Baden-Württemberg, Germany | ||
immatics biotechnologies | $63M | 21 Sep 2010 | Germany, Baden-Württemberg, Germany | ||
CureVac | $34M | 10 May 2010 | Germany, Baden-Württemberg | ||
Apogenix | $32M | 30 Apr 2008 | Heidelberg, Baden-Württemberg, Germany |
